Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Drugs Derived from New Compound Could Cure Three Tropical Diseases

By Ryan Bushey | August 8, 2016

Scientists are one step closer to developing a potent treatment for Chagas disease, leishmaniasis, and human trypanosomiasis. All three are tropical diseases that affect 20 million people worldwide and can cause an estimated 50,000 deaths a year.

One feature these diseases all have in common is that parasites with similar biologies and genomic sequences induce these infections, according to University of York. However, each pathogen causes different symptoms.

The researchers scanned a library owned by Novartis, which was filled with over three million chemical compounds. A phenotypic screen was performed against the live parasites using these elements in order to identify the most potent.

Please follow R&D Magazine on LinkedIn

The final compound, named GNF6702, had the greatest impact against a weak spot found in all three parasites, reported Reuters.

The compound was modified to test in mice. Results showed GNF6702 could successfully cure the disease in the animal subjects without causing harmful side effects.

No dangerous side effects in mice may mean this compound could present a safer alternative to existing tropical disease drugs.

The next phase of this project will include toxicity testing before moving onto human trials.

The study was published in the journal Nature.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE